Subjective impact of osteoarthritis flare-ups on patients' quality of life

1477-7525-3-14 1477-7525 Research Subjective impact of osteoarthritis flare-ups on patients' quality of life Majani Giuseppina gmajani@fsm.it Giardini Anna agiardini@fsm.it Scotti Aurelio a.scotti@italfarmaco.com

Psychology Unit, Fondazione S. Maugeri, Clinica del Lavoro e della Riabilitazione, IRCCS, Istituto Scientifico di Montescano (PV), Italy

Scientific Department, Italfarmaco SpA, Milan, Italy

Health and Quality of Life Outcomes 1477-7525 2005 3 1 14 http://www.hqlo.com/content/3/1/14 15771777 10.1186/1477-7525-3-14 07 1 2005 16 3 2005 16 3 2005 2005 Majani et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Background

Clinical trials on osteoarthritis (OA) flare-ups treatment usually focus only on objective measures of health status, albeit recent literature suggestions on the importance of patients' subjectivity. Aim of the study was to evaluate the effects of OA and of its different types of medical treatment(s) on Health Related Quality of Life (HRQoL) in terms of both subjective satisfaction and functional status.

Methods

An observational study on prospective data collected from the Evaluation of Quality of life in OA (EQuO) clinical trial (April 1999-November 2000) was conducted; outpatients from 70 participating centers (Orthopedy or Rheumatology Departments in Italy) with a diagnosis of OA of the hip or knee were consecutively enrolled. Patients were observed at OA flare-ups (baseline) and at follow up 4 weeks after treatment. Patients' objective and subjective HRQoL were assessed by means of the SF-36 and the Satisfaction Profile (SAT-P, which focuses on subjective satisfaction); Present Pain at baseline and Pain Relief at follow up were also evaluated.

Results

Among the 1323 patients, 1138 (86%) were prescribed one drug/treatment of osteoarthritis, 169 (13%) 2 drugs/treatments, and 16 (1%) 3 drugs/treatments; most of treatments involved the prescription of NSAIDs; non-coxib, COX2 selective NSAIDs were prescribed in about 50% of patients. Follow-up visits were performed after 29.0 days on average (± 7.69 SD). For all SF-36 domains, all SAT-P items and factors, the differences between baseline and follow up scores resulted statistically significant (p < 0.001), enlighting an improvement both in health status and in subjective HRQoL.

Conclusion

Besides the classic health status measures, the assessment of patients' subjective satisfaction provides important clues on treatments efficacy of OA within the patient-centered medicine model. In clinical practice this could lead to a better doctor-patient communication and to higher levels of treatment adherence.

Background

The impact of osteoarthritis (OA) on patient's functional levels is well known 123. Pain and physical limitations constitute difficulties patients have to deal with 45 and require long term pharmacological treatment and physical therapies.

Usually OA affects elderly people, and is one of the main causes of physical disability. In OA patients, Health Related Quality of Life (HRQoL) and activities of daily living are negatively affected. Significant work disability, reduced ability to deal with household duties and sleep disorders are reported in patients with symptoms of OA flare-ups, together with dysfunctions in the areas of ambulation, body-care and movement (in terms of perceived health status), and emotional behaviour (in terms of perceived psychological functioning) 1245678.

As a chronic condition, the impact of OA has been studied mainly focusing on its consequences on health status. Similarly, treatment efficacy is assessed within the context of health status and/or symptomatology in many clinical trials 679101112. However, health status and symptomatology can be considered only two components of HRQoL 13 and little is known about the impact of OA and its treatments on patient's subjective perspective, in spite of increasing attention on this topic 141516171819.

In literature, HRQoL refers to patients' appraisals of their current levels of functioning and satisfaction, compared to what they perceive to be ideal 20. HRQoL assessment allows a subject to express his or her ability to perform daily activities across many domains which include physical, social and cognitive functioning, role activities and emotional wellbeing. Besides, "...how a subject feels about the performace of each of those activities may be assessed separately by measuring satisfaction for each domain." 21. The subjective implications of HRQoL, within the context of patient centred medicine, have been already stressed by suggestions from recent reliable scientific literature 151718192021222324.

The aim of the present study is to evaluate the effects of OA and of its different types of medical treatment(s) on HRQoL in terms of both subjective satisfaction and functional status.

Methods

Patient population and procedure

Data from collaborating, educated outpatients aged 50–80 years with a diagnosis of OA of the hip or knee according to the criteria of the American College of Rheumatology 25 were collected in this observational, prospective study.

Outpatients (n = 1340) were consecutively enrolled in 70 Italian participating centers (Orthopedy or Rheumatology Departments, listed in Appendix A [see additional file]) from April 1999 to November 2000. 147 patients withdrawn OA treatment before follow-up visit.

Additional File 1

Appendix A – Participating Centers

Click here for file

All patients signed an informed consent in which the purposes of the study (HRQoL assessment and treatment efficacy, as primary and secondary outcomes respectively) were clearly stated. Approval for this research was obtained by the ethics committee, patients did not receive any remuneration for their participation.

Patients with concomitant osteoarticular disorders, impairment of motor function not due to OA of the hip or knee, concomitant systemic disease(s) affecting HRQoL or requiring NSAIDs/steroids use on a regular basis were not included into the study, in order to avoid biases in the results due to treatments other than OA treatments.

Patients were observed at OA flare-ups, when attending for a visit (baseline) and at follow up 4 weeks after treatment. According to the observational design of this trial, no "study treatments" were assigned to patients, but any drug(s)/medical treatment(s) considered by the physician as adequate to the patient's clinical condition was freely prescribed; therefore patients were not previously randomized to treatment.

During both visits, patients were administered the following: the Visual Analogue Scale (VAS) 26 on Present Pain (baseline) or on Pain Relief (follow up); the Medical Outcomes Study Short-Form 36 Health Status Survey (SF-36) 27 in its validated Italian version 2829 and the Satisfaction Profile (SAT-P) 30.

Moreover, at follow up, the global assessments of efficacy and tolerability of the medical treatment(s) prescribed for OA flare ups (expressed by the patient and by the physician according to a 4 point semi-quantitative rating scale: excellent – good – moderate – poor) were collected. Side effects to this/these treatment(s), if any, were registered as well.

The assessment procedure was standardized for all the participating centres. During the visit patients were invited to compile alone all the questionnaires and rating scales, only if required patients were assisted by a trained health professional.

Self-reporting bias in HRQoL improvements was kept under control by the assessment procedure and by the adoption of valid and reliable questionnaires.

Measures

Visual Analogue Scale

The VAS is perhaps the most widely used instrument for the measurement of pain intensity. The classic version of the VAS was administered: 10 centimeter line, horizontal. "It is a simple, robust, sensitive, and reproducible instrument that enables a patient to express the severity of his pain in such a way that it can be given a numerical value." 26 Its psychometric properties and its utility in clinical trials have been confirmed 283132. VAS on Present Pain ranged from "no pain" to "the worst pain possible"; VAS on Pain Relief ranged from "no pain relief" to "the maximum pain relief". Scores ranged from 0 to 100.

SF-36

The SF-36 is a well known self-administered and generic health status measure which encompasses 8 domains related to daily life activities: physical functioning, role limitations due to physical problems, role limitations due to emotional problems, vitality, bodily pain, social functioning, mental health and general health perception 333435. Each domain scores from 0 (lowest level of functioning) to 100 (highest level of functioning). The instrument has been extensively validated within the Medical Outcome Study 33 and in other settings 34.

Satisfaction Profile

The SAT-P is a self-administered, generic questionnaire which provides a satisfaction profile in daily life and can be considered as an indicator of subjective QoL. Satisfaction can be defined as the cognitive product of the comparison between ideal life and reality, and can therefore be quantitatively measured. The subject is asked to evaluate his/her satisfaction about 32 life aspects with reference to the last month (on 32 10 cm horizontal VAS) independently of his/her objective health status (for example: "How satisfied have you been in the last month with your Resistance to physical fatigue?"; "How satisfied...with your Mood?"; "How satisfied...with your Emotional stability?"). It provides 32 individual scores and 5 factor scores, all ranging from 0 (lowest level of satisfaction) to 100 (highest level of satisfaction). Together with its ability to detect patient's subjective satisfaction, the SAT-P addresses some aspects of daily life which are not included in SF-36 items (i.e. sleep, sexual life, quality of couple relationship, eating, self-confidence, resistance to stress, etc.). Its psychometric properties and clinical utility have been confirmed 303637.

Statistical analyses

Sociodemographic data and clinical values were analysed by means of descriptive statistics. Since the incidence of withdrawals resulted low, analyses were performed on complete cases and no solutions for handling missing data was adopted.

Baseline and follow-up of SF-36 and SAT-P item and factor scores were compared by means of Analusis of Covariance (ANCOVA). Moreover, ANCOVAs were adopted in order to evaluate the impact of clinical variables on SF-36 and SAT-P factor delta scores (calculated subtracting the follow-up scores from baseline scores). The variables included into the models were: age, gender, body weight, OA localization (hip, knee, or both), VAS Present Pain, presence of concomitant disease(s), type of treatment (COX2 selective NSAIDs vs. other treatments). Results were summarized using mean ± SE for continuous variables and frequency (absolute and percent) for categorical variables. All p values are two-tailed and p < .05 was considered statistically significant. All computations were carried-out by resorting to SAS 8.0 procedures.

Results

Patients demographic and clinical characteristics (OA localization (hip/knee/both), VAS Present Pain, type of medical treatment(s) of OA flare-ups, concomitant diseases and treatments are shown in Table 1. Patients' baseline VAS Present Pain resulted consistent with a clinical condition of moderate to severe rheumatic disease.

Table 1

Patients' characteristics

Gender (F/M)

795/528

Age (years, mean ± SD)

64.4 ± 10.3

Marital status:

Single, n (%)

72 (5.4)

Married, n (%)

922 (69.7)

Widowed, n (%)

220 (16.6)

Separated/divorced, n (%)

13 (1.0)

Missing, n(%)

96 (7.3)

Educational level:

Primary school, n (%)

548 (41.4)

Junior high school, n (%)

325 (24.6)

Senior high school, n (%)

280 (21.2)

Degree/Master/PhD, n (%)

103 (7.7)

Missing, n(%)

67 (5.1)

Employment status:

Employed, n (%)

434 (32.8)

Retired, n (%)

550 (41.6)

Housewife, n (%)

288 (21.8)

Missing, n (%)

51 (3.8)

Body weight (kg, mean ± SD)

73.4 ± 11.0

OA localization:

Knee, n (%)

658 (49.7)

Hip, n (%)

463 (35.1)

Knee + hip, n (%)

202 (15.2)

VAS Present Pain (mm, mean ± SD)

67.7 ± 17.0

Concomitant diseases, n (%)

632 (47.8)

Concomitant treatments, n (%)

444 (33.6)

The most frequent concomitant diseases were: hypertension (19.1%), metabolic and nutritional disorders (9.2%), muscoloskeletal, connective tissue and bone disorders (8.2%) and gastrointestinal system disorders (4.3%). The most frequently prescribed concomitant treatments were: cardiologic drugs (9.7%) and antihypertensive (9.4%), antidiabetic drugs (8.4%), antithrombotic agents (4.5%), antiacids (6.7%), sedatives (4.8%). 1138 patients (86%) were prescribed one drug/treatment of OA, 169 patients (13%) 2 drugs/treatments, and 16 patients (1%) received 3 drugs/treatments. Most of treatments involved the prescription of NSAIDs; non-coxib, COX2 selective NSAIDs (nimesulide betadex and nimesulide, the only two COX2 selective NSAIDs available in Italy at the time of this study) were prescribed in about 50% of patients (Table 2).

Table 2

Treatments prescribed for osteoarthritis flare-ups

% patients

COX2 NON-SELECTIVE NSAIDs

Arylacetic acid derivatives (diclofenac, indomethacin, sulindac, etc.)

221

16.7

Arylpropionic acid derivatives (ibuprofen, naproxen, ketoprofen, etc.)

165

12.5

Oxycams (piroxicam, tenoxicam, etc.)

181

13.7

Others (nabumetone, glucosamine, diacerein, etc.)

107

8.1

COX2 SELECTIVE NSAIDs

Nimesulide betadex (or nimesulide)

689

52.1

OTHER DRUGS/TREATMENTS

Various, systemic (ASA, paracetamol, corticosteroids, centrally acting myorelaxants)

3.5

Various, topical (transcutaneous or intraarticular)

3.3

Physical treatment (mobilization, iontophoresis, etc.)

4.5

Follow-up visits were performed after 29.0 days on average (± 7.69 SD). Only a small number of patients (17; 1.2%) did not attend follow-up visit.

HRQoL assessment: SF-36

For all SF-36 domains, the difference between baseline and follow up scores resulted statistically significant (p < 0.001) (Table 3).

Table 3

SF 36 scores (Mean ± SE). Baseline vs Follow-up scores. At the ANCOVAs: p < 0.001 for all domains

SF-36 domains

Baseline

Follow up

Physical Functioning

47.9 ± 0.7

59.3 ± 0.7

<.001

Role Physical

27.8 ± 1.0

48.0 ± 1.1

<.001

Bodily Pain

31.7 ± 0.4

50.5 ± 0.5

<.001

General Health

45.8 ± 0.5

50.0 ± 0.5

<.001

Vitality

46.5 ± 0.5

53.2 ± 0.5

<.001

Social Functioning

44.1 ± 0.6

65.4 ± 0.6

<.001

Role Emotional

46.9 ± 1.2

65.7 ± 1.1

<.001

Mental Health

59.2 ± 0.5

65.4 ± 0.5

<.001

Baseline Present Pain was associated with almost all the SF-36 domains (Table 4). The presence of concomitant disease(s) resulted in a statistically significant association with 4 domains: Role Physical, Bodily Pain, General Health, Social Functioning. The type of OA treatment was associated with Physical Functioning and Bodily Pain. OA localization and age was associated with only one domain: Physical Functioning and Role Physical respectively. Gender and body weight did not correlate with any SF-36 domain.

Table 4

Detected statistical significances on SF-36 delta scores. The p values resulted from the ANCOVAs are indicated.

SF-36 domains

Covariates

Age

Gender

Body weight

OA localization

Present Pain

Concomitant diseases

Treatment

Physical Functioning

0.021

0.0001

0.020

Role Physical

0.022

0.007

Bodily Pain

0.0001

0.006

General Health

0.0001

0.003

Vitality

0.0001

Social Functioning

0.0001

0.003

Role Emotional

0.007

Mental Health

0.0001

HRQoL assessment: SAT-P factors

All the differences between baseline and follow up SAT-P factor scores were statistically significant (p < 0.001) (Table 5).

Table 5

SAT-P factor scores (M ± SE). Baseline vs Follow-up scores. At the ANCOVAs: p < 0.001 for all Factors.

SAT-P Factors

Baseline

Follow up

Psychological functioning

59.3 ± 0.6

65.5 ± 0.5

p <.001

Physical functioning

41.3 ± 0.5

51.9 ± 0.5

p <.001

Work

53.3 ± 0.7

57.8 ± 0.7

p <.001

Sleep/Eating/Leisure

55.4 ± 0.5

60.9 ± 0.5

p <.001

Social functioning

66.0 ± 0.6

70.8 ± 0.5

p <.001

Baseline pain was significantly associated with all SAT-P factors (Table 6). The presence of concomitant disease(s) was in a statistically significant association with 3 out of 5 factors: Psychological functioning, Sleep-Eating-Leisure, Social functioning. OA treatment was associated with the factor Sleep-Eating-Leisure.

Table 6

Detected statistical significances on SAT-P factors. The p values resulted from the ANCOVAs are indicated

SAT-P Factors

Covariates

Age

Gender

Body weight

OA localization

Present Pain

Concomitant diseases

Treatment

Psychological functioning

0.0001

0.022

Physical functioning

0.0001

Work

0.007

Sleep/Eating/Leisure

0.0001

0.007

0.026

Social functioning

0.0001

0.018

HRQoL assessment: SAT-P items

Figure 1 shows the graphic representation of baseline and follow up SAT-P item scores. All the differences were statistically significant (p < 0.001).

Figure 1

SAT-P items: mean scores at baseline and at follow-up

SAT-P items: mean scores at baseline and at follow-up. For all the differences (ANCOVAs) p < 0.001.

Clinical outcome of OA treatment: Efficacy and Tolerability

At follow-up, mean VAS Pain Relief was 61.1 mm (± 24.3 SD).

In 65% of cases treatment efficacy was evaluated as good or excellent by patients themselves, in 67% of cases it was evaluated as good or excellent by physicians. In 81% of cases treatment tolerability was evaluated as good or excellent by patients themselves, in 84% of cases it was evaluated as good or excellent by physicians. It was evaluated as poor in 7% and 6% of cases respectively (Table 7).

Table 7

OA treatments' evaluations (efficacy and tolerability)

Poor

Moderate

Good

Excellent

Missing data

n (%)

Efficacy – patients

163 (12.3)

288 (21.8)

634 (47.9)

227 (17.2)

11 (0.8)

Efficacy – physicians

129 (9.8)

292 (22.1)

634 (47.9)

257 (19.4)

11 (0.8)

Tolerability – patients

93 (7.1)

147 (11.1)

712 (53.8)

359 (27.1)

12 (0.9)

Tolerability – physicians

79 (6.0)

122 (9.2)

703 (53.1)

407 (30.8)

12 (0.9)

11.1% of patients reported side effects to medical treatment of OA; most of these reactions involved the gastrointestinal system. Poor tolerability led to treatment withdrawal in 6.2% of patients.

Discussion

Our study represents, to our knowledge, the largest observational prospective clinical trial carried out in OA patients' subjective HRQoL. The sample size and the very small number of drop-outs could be considered the strenghts of the study.

A limit of the study could be considered the adoption of the SAT-P which is a new questionnaire, validated on the Italian population 30, but not previously used in clinical trials or in OA patients. Nevertheless, its psychometric properties have been previously confirmed, and moreover it is the only Italian questionnaire specifically aimed at assessing subjective satisfaction in daily life, independently of the presence of a disease. Its user friendly structure and its easily comprehensible graphical representation could be considered substantial methodological facilities both in research and in clinical practice.

Finally, the coherence between the data provided by the two HRQoL instruments could confirm that health status and subjective satisfaction partially overlap, and allows us to study the same phenomenon from two different points of view: the objective and the subjective. This could therefore be considered the added value of the study.

Considering the whole sample, SF-36 results confirm what previous studies have already enlightened in clinical trials: the SF-36 is, according to Kosinski et al. 35, a suitable instrument for assessing health status in OA, and medical treatment improves functionality levels in daily life aspects.

The same conclusions could be drawn for the SAT-P: on the whole sample a general improvement of satisfaction levels can be observed in all the 32 items considered. In other words, pharmacological treatment has a significant positive impact on patients' both objective functioning and subjective well-being 16.

Thanks to the sinergic utility of the two instruments it has been possible to enlight results otherwise left unperceived and whose positive value on patients' life is unquestionable.

Further investigations are needed in order to better clarify the relationships between perceived pain and pain relief and patients' HRQoL. Mastery, self-efficacy and coping abilities could be significant mediators between these two constructs 3839.

Conclusion

From both an objective and a subjective point of view, OA flare-ups' treatment has proved to have positive effects on HRQoL. The sinergic use of a health status measure (SF-36) and of a tool addressing subjective satisfaction (SAT-P) allows to wider the focus on patients' life.

This methodological approach could help clinicians and researchers in transferring into practice the ICF model issues 40, with special attention on Activity and Participation and on Environmental Factors.

List of abbreviations

ANCOVA Analysis of Covariance

HRQoL Health Related Quality of Life

NSAID Non Steroid Anti Inflammatory Drugs

OA Osteoarthritis

SAT -P Satisfaction Profile

SF-36 Medical Outcome Study Short-Form 36 Health Status Survey

VAS Visual Analogue Scale

Competing interests

The author AS is employee of the company that partially funded the study.

Authors' contributions

GM: responsible for the design of the study, contributed to the statistical evaluation, contributed to the writing of the paper.

AG: responsible for the statistical evaluation, contributed to the writing of the paper.

AS: contributed to the design of the study and data collection, contributed to the statistical evaluation, contributed to revise the manuscript.

Acknowledgements

This study has been partially funded by Italfarmaco SpA, Milan, Italy. We would gratefully acknowledge the recruitment and data collection of the many physicians and nurses who collaborated to our study (in Appendix A all the participating centers are listed [see additional file]).

Health-related quality of life in patients with osteoarthritis in a family practice setting de Bock GH Kaptein AA Touw-Otten F Mulder JD Arthritis Care Res 1995 8 88 93 7794991 Quality of life in elderly subjects with pain in the hip or knee Hopman-Rock M Kraaimaat FW Bijlsma Qual Life Res 1997 6 67 76 10.1023/A:1026421629416 9062444 Health impact of pain in the hip region with and without radiographic evidence of osteoathritis: a study of new attenders to primary care Birrel F Croft P Cooper C Hosie G Macfarlane G Silman A Ann Rheum Dis 2000 59 857 863 10.1136/ard.59.11.857 11053061 Impact of osteoarthritis and analgesic treatment on quality of life of an elderly population Briggs A Scott E Steele K Ann Pharmacother 1999 33 1154 1159 10.1345/aph.18411 10573311 Factors associated with functional impairment in symtomatic knee osteoarthritis Creamer P Lethbridge-Cejku M Hochberg MC Rheumatology 2000 39 490 496 10.1093/rheumatology/39.5.490 10852978 Health-related quality of life assessments in osteoarthritis during NSAID treatment de Bock GH Hermans J van Marwijk HWJ Kaptein AA Mulder JD Pharm World Sci 1996 18 130 136 10.1007/BF00717728 8873228 Quality of life assessment during six months of NSAID treatment [Gonarthrosis and quality of life (GOAL) Study] La Montagna G Tirri G Cacace E Perprgnano G Covelli M Pipitone V D'Agostino P Magarò M Ferraccioli G Mascia MT Manzini E Minari C Barreca C Marcolongo R Paresce E Colombo B Clin Exp Rheumatol 1998 16 49 54 9543561 Gastrointestinal symptoms and health related quality of life in patients with arthritis Wolfe F Kong SX Watson DJ J Rheumatol 2000 27 1373 1378 10852256 Topical diclofenac versus placebo: a double blind, randomized clinical trial in patients with osteoathritis of the knee Grace D Rogers J Skeith K Anderson K J Rheumatol 1999 26 2659 2663 10606379 Evaluation of the functional status aspects of health-related quality of life of patients with osteoarthritis treated with celecoxib Zhao SZ McMillen JI Markenson JA Dedhiya SD Zhao WW Osterhaus JT Yu SS Pharmacotherapy 1999 19 1269 1278 10.1592/phco.19.16.1269.30879 10555933 Health-related quality-of-life effects of oxaprozin and nabumetone in patients with osteoarthritis of the knee Zhao SZ Dedhiya SD Bocanegra TS Fort JG Kuss ME Rush SM Clin Ther 1999 21 205 217 10.1016/S0149-2918(00)88279-X 10090436 Safety and efficacy of meloxicam in the treatment of osteoarthritis: a 12-week, double-blind, multiple-dose, placebo-controlled trial Yocum D Fleischmann R Dalgin P Caldwell J Hall D Roszko P Arch Intern Med 2000 160 2947 2954 10.1001/archinte.160.19.2947 11041902 Distinguishing between quality of life and health status in quality of life research: a meta-analysis Smith KW Avis NE Assmann SF Qual Life Res 1999 8 447 459 10.1023/A:1008928518577 10474286 A critical appraisal of the quality of quality-of-life measurements Gill TM Feinstein AR JAMA 1994 272 619 626 10.1001/jama.272.8.619 7726894 The patient-physician relationship: JAMA focuses of the center of medicine Glass RM Editorial JAMA 1996 275 147 148 10.1001/jama.275.2.147 8531312 What are quality of life measurements measuring? Muldoon MF Barger SD Flory JD Manuck SB BMJ 1998 316 542 545 9501721 Toward a theoretical model of quality-of-life appraisal: Implications of findings from studies of response shift Rapkin BD Shwartz CE Health and Quality of Life Outcomes 2004 2 14 408464 15023229 10.1186/1477-7525-2-14 Reconsidering the psychometrics of quality of life assessment in light of response shift and appraisal Shwartz CE Rapkin BD Health and Quality of Life Outcomes 2004 2 16 408465 15038830 10.1186/1477-7525-2-16 Patients' needs, satisfaction, and health related quality of life: Towards a comprehensive model Asadi-Lari M Tamburini M Gray D Health and Quality of Life Outcomes 2004 2 32 471563 15225377 10.1186/1477-7525-2-32 Measuring quality of life today: methodological aspects Cella DF Tulsky DS Oncology 1990 5 29 38 Understanding and using health-related quality of life instrument within clinical research studies Berzon RA Quality of Life Assessment in Clinical Trials New York: Oxford University Press Staquet MJ, Hays RD, Fayers PM 1998 3 15 Measuring quality of life. Is quality of life determined by expectations or experience? Carr AJ Gibson B Robinson PG BMJ 2001 322 1240 3 10.1136/bmj.322.7296.1240 11358783 Measuring quality of life. Using quality of life measures in the clinical setting Higginsin IJ Carr AJ BMJ 2001 322 1297 300 10.1136/bmj.322.7297.1297 11375237 Measuring quality of life. Are quality of life measures patient centred? Carr AJ Higginson IJ BMJ 2001 322 1357 60 10.1136/bmj.322.7298.1357 11387189 The Classification of Osteoarthritis. Journal Rheumatology Altman RD 2001 22 suppl 43 42 43 Visual Analogue Scales Huskisson EC Pain measurement and assessment New York: Raven Press Melzack R 1983 33 37 Ware JE Jr Snow KK Kosinski M Gandek B SF-36 Health Survey: Manual and interpretation guide Boston, Mass: The Health Institute, New England Medical Center 1993 Apolone G Mosconi P Ware JE Jr Questionario sullo stato di salute SF-36: manuale d'uso e guida all'interpretazione dei risultati Milano: Guerini e Associati 1997 The Italian SF-36 Health Survey: traslation, validation and norming Apolone G Mosconi P J Clin Epidemiol 1998 51 1025 1036 10.1016/S0895-4356(98)00094-8 9817120 Satisfaction Profile (SAT-P) in 732 patients: focus on subjectivity in HRQoL assessment Majani G Pierobon A Giardini A Callegari S Psychol Health 2000 15 409 422 The subjective experience of acute pain: An assessment of the utility of 10 indices Jensen MP Karoly P O'Riordan EF Bland F Jr Burns RS Clin J Pain 1989 5 153 159 2520397 Pain intensity measurement on chronic low back pain Strong J Ashton R Chant D Clin J Pain 1991 7 209 218 1839716 Functional status and well-being of patients with chronic conditions Stewart AL Greenfield S Hays RD Wells K Rogers WH Berry SD McGlynn EA Ware JE Jr JAMA 1989 262 907 913 10.1001/jama.262.7.907 2754790 Validating the SF-36 Health Survey Questionnaire: new outcome measure for primary care Brazier JE Harper R Jones NMB O'Cathain A Thomas KJ Usherwood T Westlake L BMJ 1992 305 160 164 1285753 The SF-36 Health Survey as a generic outcome measure in clinical trials of patients with osteoathritis and rheumatoid arthritis: tests of data quality, scaling assumptions and score reliability Kosinski M Keller SD Hatoum HT Kong SX Ware JE Med Care 1999 37 Suppl MS10 22 10.1097/00005650-199905001-00002 Relationship between psychological profile and cardiological variables in chronic heart failure: the role of patient subjectivity Majani G Pierobon A Giardini A Callegari S Opasich C Cobelli F Tavazzi L Eur Heart J 1999 20 1579 1586 10.1053/euhj.1999.1712 10529326 Health-related quality of life assessment in young adults with seasonal allergic rhinitis Majani G Baiardini I Giardini A Senna GE Minale P D'Ulisse S Ciprandi G Canonica GW Allergy 2001 56 313 317 10.1034/j.1398-9995.2001.00852.x 11284798 Learning to live with the pain: acceptance of pain predicts adjustment in persons with chronic pain McCracken LM Pain 1998 74 21 27 10.1016/S0304-3959(97)00146-2 9514556 Self-efficacy as a mediator of the relationship between pain intensity, disability and depression in chronic pain patients Arnstein P Caudill M Mandle CL Norris A Beasley R Pain 1999 80 483 491 10.1016/S0304-3959(98)00220-6 10342410 World Health Organization International Classification of Functioning, Disability and Health World Health Organization: Geneva 2001